Estradiol benzoate butyrate/algestone acetophenide explained

Estradiol benzoate butyrate/algestone acetophenide, also known as estradiol benzoate butyrate/dihydroxyprogesterone acetophenide (EBB/DHPA) and sold under the brand names Neolutin N, Redimen, Soluna, and Unijab, is a form of combined injectable birth control which is used in Peru and Singapore.[1] [2] [3] [4] [5] [6] It contains estradiol benzoate butyrate (EBB), an estrogen, and algestone acetophenide (dihydroxyprogesterone acetophenide; DHPA), a progestin. The medication is given once per month by injection into muscle.

Medical uses

EBB/DHPA is used as a once-a-month combined injectable contraceptive to prevent pregnancy in women.

Available forms

EBB/DHPA contains 10 mg estradiol benzoate butyrate (EBB), an estrogen, and 150 mg algestone acetophenide (dihydroxyprogesterone acetophenide; DHPA), a progestin.

Pharmacology

Pharmacodynamics

EBB/DHPA has been said to have relatively weak estrogenic activity and has been described as "progestogen-dominant".

Pharmacokinetics

EBB is said to have a shorter duration than estradiol enantate of about 3 weeks.[7] EBB/DHPA was developed because it was thought that the duration of EBB would be more suitable for use as a once-monthly combined injectable contraceptive than estradiol enantate in estradiol enantate/algestone acetophenide.

Society and culture

Brand names

EBB/DHPA is marketed under the brand names Neolutin N, Redimen, Soluna, and Unijab.[8] It was originally developed under the tentative brand name Unimens, but ultimately was not marketed under this particular brand name.[9] [10] [11]

Availability

EBB/DHPA is available only in Peru and Singapore.

See also

Notes and References

  1. Toppozada M . The clinical use of monthly injectable contraceptive preparations . Obstet Gynecol Surv . 32 . 6 . 335–47 . June 1977 . 865726 . 10.1097/00006254-197706000-00001 .
  2. Book: IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. World Health Organization. International Agency for Research on Cancer. Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy. 2007. World Health Organization. 978-92-832-1291-1. 433, 467.
  3. Book: IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. International Agency for Research on Cancer. Hormonal Contraception and Post-menopausal Hormonal Therapy. 1 January 1999. IARC. 978-92-832-1272-0. 65. 16 September 2018. 28 August 2021. https://web.archive.org/web/20210828080855/https://monographs.iarc.who.int/wp-content/uploads/2018/06/mono72.pdf. dead.
  4. Web site: Farmaco SOLUNA 150 + 10 registrado en Perú.
  5. Web site: Unijab Dosage & Drug Information | MIMS Singapore.
  6. Web site: SOLUNA . www.corporacionmisalud.com . dead . https://web.archive.org/web/20141005184908/http://corporacionmisalud.com/sistema/vademecum/PLM/productos/32499.htm . 2014-10-05.
  7. Book: Mokhtar K. Toppozada . Monthly Injectable Contraceptives . 93–103 . Alfredo Goldsmith . Mokhtar Toppozada . Long-Acting Contraception . 1983 . 35018604 .
  8. Web site: Archived copy . 2019-02-25 . 2019-02-25 . https://web.archive.org/web/20190225103155/https://www.drugs.com/international/soluna.html . dead .
  9. Book: Elsayed Saad Eldin Hafez. Human reproduction: conception and contraception. 1980. Harper and Row. 978-0-06-141066-6.
  10. Newton JR, D'arcangues C, Hall PE . A review of "once-a-month" combined injectable contraceptives . J Obstet Gynaecol (Lahore) . 4 Suppl 1 . S1–34 . 1994 . 12290848 . 10.3109/01443619409027641.
  11. Toppozada MK . Existing once-a-month combined injectable contraceptives . Contraception . 49 . 4 . 293–301 . April 1994 . 8013216 . 10.1016/0010-7824(94)90029-9 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Estradiol benzoate butyrate/algestone acetophenide".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.